Roivant Sciences (ROIV) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Royalty Pharma (RPRX) over the past year, gaining 113.4% versus a gain of 56.1%. Over five years, ROIV leads with a +468.3% price change compared with +46.4% for RPRX. Royalty Pharma is the larger company by market cap ($32.48 billion vs $24.71 billion), about 1.3 times the size.
Royalty Pharma pays a dividend yielding 1.62%, while Roivant Sciences does not currently pay one. Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ROIV | RPRX |
|---|---|---|
| Share price | $34.21 | $56.21 |
| Market cap | $24.71B | $32.48B |
| 1-day change | -1.55% | -0.97% |
| YTD return | +57.65% | +45.47% |
| 1-year return | +113.41% | +56.05% |
| 5-year return | +468.27% | +46.42% |
| P/E ratio (TTM) | — | 29.90 |
| Forward P/E | — | 9.80 |
| EPS (TTM) | $-0.53 | $1.88 |
| Dividend yield | 0.00% | 1.62% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | $8.26M | $2.38B |
| Revenue growth (YoY) | -71.57% | +5.06% |
| Net income (latest FY) | $-299.77M | $770.95M |
| Operating margin | -6235.69% | 65.58% |
| Net margin | -3629.19% | 32.42% |
| 52-week high | $42.50 | $64.38 |
| 52-week low | $15.90 | $35.23 |
| Distance from 52-week high | -19.51% | -12.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +40.54% | +16.31% |
| Average volume | 7.04M | 2.92M |
| Shares outstanding | 722.32M | 445.28M |
| Employees | 721 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed RPRX by 57.4 percentage points over the past year.
- Royalty Pharma offers a meaningfully higher dividend yield (1.62% vs 0.00%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- Royalty Pharma grew revenue faster in its latest fiscal year (+5.06% vs -71.57%).
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ROIV vs RPRX FAQ
Which is bigger, Roivant Sciences or Royalty Pharma?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.48B compared with $24.71B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ROIV or RPRX?
ROIV returned +113.41% over the past 12 months, compared with +56.05% for RPRX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Roivant Sciences or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.62%, while Roivant Sciences does not currently pay a regular dividend.
Are Roivant Sciences and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.